Familial Partial Lipodystrophy (FPLD) Pipeline Analysis 2019 (H1)

Familial Partial Lipodystrophy (FPLD) Pipeline Analysis report covers 3 drugs currently in different phases of development. FPLD is a rare, genetic condition characterized by the abnormal fat distribution in the body. Adipose tissue surrounding the internal organs and just beneath the skin is responsible for storing the fat. In people with FPLD adipose tissue is lost from the arms, legs, and buttocks and build up around the head, neck and inside the abdomen. The disease is characterized by a high level of triglycerides circulating in the body which may lead to increased risk of cardiovascular disease, pancreatitis, hepatic steatosis, and hepatic acromegaly.

The report provides Familial Partial Lipodystrophy (FPLD) treatment drugs by company, phases of development including products in the early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.

Major industry players profiled as part of the report are Akcea Therapeutics, Gemphire Therapeutics Inc., Idera Pharmaceuticals, Inc., Ionis Pharmaceuticals and Novelion Therapeutics, Inc.

Scope:

By Company
By Phase
By Molecule Type
By Region
By Route of Administration

1. Introduction

1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview

2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics

4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling

Drug Name
Generic Name
Synonyms
Company
Collaborator
Route of administration
Target
Mechanism of Action
Technology
Molecule type
CAS Number
Weight
Chemical Formula
IUPAC name
ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling

6.1. Akcea Therapeutics
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.1.5. Recent Development
6.2. Gemphire
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.2.5. Recent Development
6.3. Ionis Pharmaceuticals, Inc.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.3.5. Recent Development